Genetically Modified Herpes Virus Shows Promise Against Advanced Melanoma
LOS ANGELES COUNTY, CALIFORNIA, JUL 08 – The engineered herpes virus RP1 combined with nivolumab caused tumor shrinkage or disappearance in one-third of advanced melanoma patients in phase 1-2 trials, FDA review pending.
- At the ASCO meeting in 2025, one-third of advanced melanoma patients treated with RP1 plus nivolumab saw tumor shrinkage, with nearly one-sixth experiencing complete responses.
- Driven by the need for better treatments, the IGNYTE trial involved 140 patients with resistant advanced melanoma, which has a median survival of only a few years.
- Published phase 1-2 data show RP1, combined with nivolumab, reduces tumors beyond injection sites, with results presented at ASCO and published in the Journal of Clinical Oncology, prompting optimism from Dr. In.
- Following the FDA's January 2025 priority review, the phase 3 IGNYTE-3 trial with over 400 participants is now open, advancing RP1's regulatory path.
- Beyond injected tumors, experts predict RP1 will see broader use than T-VEC, the only oncolytic virus approved so far, potentially revolutionizing cancer immunotherapy.
18 Articles
18 Articles
RP1 Plus Nivolumab Shows Durable Response in Advanced Melanoma
A genetically engineered herpes simplex virus (HSV-1) named RP1, when combined with immunotherapy, reduces or eliminates melanoma tumors in one-third of clinical trial patients, according to a new study. An analysis of the Phase I–II of the IGNYTE clinical trial, was published in the Journal of Clinical Oncology and presented recently at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. The data showed that one-third of patie…
Genetically modified herpes virus shows promise against advanced melanoma
The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around the mouth.
Medical Xpress
University of Southern CaliforniaCancer-fighting herpes virus shown to be an effective treatment for some advanced melanoma
The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around the mouth.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
